Alkermes

World Rank (Jan-05-2024)

3,032

Market Cap (Jan-05-2024)

4.784 Billion USD

World Rank (Jul-30-2023)

3,088

Market Cap (Jul-30-2023)

4.778 Billion USD

World Rank (Jan-07-2022)

3,992

Market Cap (Jan-07-2022)

3.883 Billion USD

World Rank (Jan-01-2021)

4,130

Market Cap (Jan-01-2021)

3.175 Billion USD

Headquarters Country

Ireland

Nasdaq / NYSE Code

ALKS

Market Cap (Mar-08-2026)

4.77

Employee Count

2,280

Employee Count as of Date

As on 2023

Headquarters City/State

Dublin

World Region

Europe

World Subregion

Northern Europe

Annual Revenue in USD

1,111 Million USD

Annual Operating Income in USD

-142 Million USD

Annual Net Income in USD

-158 Million USD

Annual Results for Period Ending

Dec-2022 ending year

Total Assets in USD

1,963 Million USD

Total Liabilities in USD

920 Million USD

Total Equity in USD

1,043 Million USD

Balance Sheet for Period Ending

Dec-2022 ending year

Business Sector

Company Website

Wikipedia

Yahoo

Yahoo @ Nasdaq

Company Profile

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. Headquarters is in Dublin, Ireland.

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases.

The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer.

As of February-2021, it had approximately 2,245 full time employees, of which approximately 1,834 were based in the U.S. and 411 were based in Ireland.

Founded Year

1987

IPO Year

1991

Stock Exchange

Nasdaq

Company SubCategory

Top Healthcare Companies in Europe

Nasdaq Sector

Health Care

Nasdaq Industry

Biotechnology: Pharmaceutical Preparations